Logo image of EPZM

EPIZYME INC (EPZM) Stock Fundamental Analysis

NASDAQ:EPZM - Nasdaq - US29428V1044 - Common Stock - Currency: USD

1.47  -0.02 (-1.34%)

After market: 1.47 0 (0%)

Fundamental Rating

2

Overall EPZM gets a fundamental rating of 2 out of 10. We evaluated EPZM against 567 industry peers in the Biotechnology industry. Both the profitability and financial health of EPZM have multiple concerns. EPZM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EPZM had negative earnings in the past year.
EPZM Yearly Net Income VS EBIT VS OCF VS FCFEPZM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -50M -100M -150M -200M -250M

1.2 Ratios

Industry RankSector Rank
ROA -78.64%
ROE N/A
ROIC -67.61%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPZM Yearly ROA, ROE, ROICEPZM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 400 600 800 1K

1.3 Margins

Industry RankSector Rank
OM -370.05%
PM (TTM) -391.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPZM Yearly Profit, Operating, Gross MarginsEPZM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EPZM is destroying value.
Compared to 1 year ago, EPZM has more shares outstanding
EPZM has a worse debt/assets ratio than last year.
EPZM Yearly Shares OutstandingEPZM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
EPZM Yearly Total Debt VS Total AssetsEPZM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -8.10, we must say that EPZM is in the distress zone and has some risk of bankruptcy.
EPZM has a Debt/Equity ratio of -11.48. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -11.48
Debt/FCF N/A
Altman-Z -8.1
ROIC/WACC-5.62
WACC12.02%
EPZM Yearly LT Debt VS Equity VS FCFEPZM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 100M -100M 200M -200M 300M

2.3 Liquidity

A Current Ratio of 5.35 indicates that EPZM has no problem at all paying its short term obligations.
EPZM has a Quick Ratio of 5.19. This indicates that EPZM is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 5.35
Quick Ratio 5.19
EPZM Yearly Current Assets VS Current LiabilitesEPZM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.33% over the past year.
The Revenue has grown by 62.65% in the past year. This is a very strong growth!
Measured over the past years, EPZM shows a very strong growth in Revenue. The Revenue has been growing by 36.12% on average per year.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)62.65%
Revenue growth 3Y19.92%
Revenue growth 5Y36.12%
Sales Q2Q%111.59%

3.2 Future

EPZM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.01% yearly.
Based on estimates for the next years, EPZM will show a very strong growth in Revenue. The Revenue will grow by 57.70% on average per year.
EPS Next Y43.15%
EPS Next 2Y23.07%
EPS Next 3Y16.89%
EPS Next 5Y8.01%
Revenue Next Year28.63%
Revenue Next 2Y45.71%
Revenue Next 3Y52.93%
Revenue Next 5Y57.7%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EPZM Yearly Revenue VS EstimatesEPZM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
EPZM Yearly EPS VS EstimatesEPZM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EPZM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPZM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPZM Price Earnings VS Forward Price EarningsEPZM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.76
EPZM Per share dataEPZM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

EPZM's earnings are expected to grow with 16.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.07%
EPS Next 3Y16.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPZM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EPIZYME INC

NASDAQ:EPZM (8/11/2022, 8:00:01 PM)

After market: 1.47 0 (0%)

1.47

-0.02 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-09 2022-08-09/bmo
Earnings (Next)11-07 2022-11-07
Inst Owners0.04%
Inst Owner Change0%
Ins Owners19.61%
Ins Owner Change0%
Market Cap247.44M
Analysts77.78
Price Target3.04 (106.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -1.76
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.31
BVpS-0.12
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.64%
ROE N/A
ROCE N/A
ROIC -67.61%
ROICexc N/A
ROICexgc -82.24%
OM -370.05%
PM (TTM) -391.89%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity -11.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.35
Quick Ratio 5.19
Altman-Z -8.1
F-Score2
WACC12.02%
ROIC/WACC-5.62
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y43.15%
EPS Next 2Y23.07%
EPS Next 3Y16.89%
EPS Next 5Y8.01%
Revenue 1Y (TTM)62.65%
Revenue growth 3Y19.92%
Revenue growth 5Y36.12%
Sales Q2Q%111.59%
Revenue Next Year28.63%
Revenue Next 2Y45.71%
Revenue Next 3Y52.93%
Revenue Next 5Y57.7%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A